Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs UpdatePRNewsWire • 11/11/21
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19PRNewsWire • 10/19/21
Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung MetastasesPRNewsWire • 10/18/21
Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech SummitPRNewsWire • 09/17/21
Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment ConferencePRNewsWire • 09/08/21
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs UpdatePRNewsWire • 08/12/21
Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid LeukemiaPRNewsWire • 07/13/21
Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung MetastasesPRNewsWire • 06/21/21
Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung MetastasesPRNewsWire • 05/25/21
Moleculin Reports First Quarter 2021 Financial Results and Provides Programs UpdatePRNewsWire • 05/12/21
WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug CandidateGlobeNewsWire • 05/11/21
Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain TumorBenzinga • 04/14/21
Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of EpendymomaPRNewsWire • 04/14/21
Moleculin Biotech's Stock Is Trading Higher On Accelerated Review Tag For Annamycin In Connective Tissue CancerBenzinga • 03/30/21
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung MetastasesPRNewsWire • 03/30/21
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020PRNewsWire • 03/24/21